Article
Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.
PloS one - 1 Jan 2020
Bories Pierre, Prade Naïs, Lagarde Stéphanie, Cabarrou Bastien, Largeaud Laetitia, Plenecassagnes Julien, Luquet Isabelle, De Mas Véronique, Filleron Thomas, Cassou Manon, Sarry Audrey, Fornecker Luc-Matthieu, Simand Célestine, Bertoli Sarah, Recher Christian, Delabesse Eric
Abstract excerpt
Hypomethylating agents are a classical frontline low-intensity therapy for older patients with acute myeloid leukemia. Recently, TP53 gene mutations have been described as a potential predictive biomarker of better outcome in patients treated with a ten-day decitabine regimen., However, functional characteristics of TP53 mutant are heterogeneous, as reflected in multiple functional TP53 classifications and their...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.